Mostra i principali dati dell'item
Effect of hepatitis C virus on immunological and virological responses in HIV-infected patients initiating highly active antiretroviral therapy: a meta-analysis
dc.creator | Tsiara, C. G. | en |
dc.creator | Nikolopoulos, G. K. | en |
dc.creator | Dimou, N. L. | en |
dc.creator | Bagos, P. G. | en |
dc.creator | Saroglou, G. | en |
dc.creator | Velonakis, E. | en |
dc.creator | Hatzakis, A. | en |
dc.date.accessioned | 2015-11-23T10:51:23Z | |
dc.date.available | 2015-11-23T10:51:23Z | |
dc.date.issued | 2013 | |
dc.identifier | 10.1111/jvh.12101 | |
dc.identifier.issn | 1352-0504 | |
dc.identifier.uri | http://hdl.handle.net/11615/33893 | |
dc.description.abstract | Co-infection of human immunodeficiency virus (HIV) with hepatitis C virus (HCV) is rather common. In the era of highly active antiretroviral therapy (HAART), viral hepatitis could result in adverse outcomes in HIV+ patients. The current meta-analysis aims to evaluate the impact of HCV on immunological and virological responses after HAART initiation in HIV/HCV co-infected individuals by synthesizing the existing scientific evidence. A comprehensive search of electronic databases was performed. Eligible studies were analysed using univariate and multivariate meta-analytic methods. Totally, 21 studies involving 22533 individuals were eligible. The estimated summary difference in CD4 cell counts increase between HIV and HIV/HCV co-infected subjects after 3-12months on HAART was 34.86 cells/mm(3) [95% confidence interval (CI): 16.82-52.89]. The difference was more prominent in patients with baseline CD4 counts below 350 cells/mm(3) (38.97, 95% CI: 20.00-57.93) and attenuated 2years later (13.43, 95% CI: 0.83-26.04). The analysis of ratio measures yielded similar findings. The virological control remained unaffected by the presence of HCV (adjusted Hazard Ratio for co-infected patients vs those with HIV alone: 0.99, 95% CI: 0.91-1.07). The bivariate meta-analytic method confirmed the results of the univariate approaches. This meta-analysis supports the adverse effect of HCV on immune recovery of HIV+ patients initiating HAART, especially of those with initially impaired immunologic status. Although this effect diminishes over time, early administration of HAART in the setting of co-infection seems to be justified. | en |
dc.source.uri | <Go to ISI>://WOS:000324043500006 | |
dc.subject | antiretroviral treatment | en |
dc.subject | HCV | en |
dc.subject | HIV | en |
dc.subject | immunological response | en |
dc.subject | virological | en |
dc.subject | response | en |
dc.subject | HUMAN-IMMUNODEFICIENCY-VIRUS | en |
dc.subject | INJECTION-DRUG USERS | en |
dc.subject | IMMUNE RECOVERY | en |
dc.subject | DISEASE PROGRESSION | en |
dc.subject | POSITIVE PATIENTS | en |
dc.subject | NATURAL-HISTORY | en |
dc.subject | COINFECTION | en |
dc.subject | IMPACT | en |
dc.subject | COHORT | en |
dc.subject | HAART | en |
dc.subject | Gastroenterology & Hepatology | en |
dc.subject | Infectious Diseases | en |
dc.subject | Virology | en |
dc.title | Effect of hepatitis C virus on immunological and virological responses in HIV-infected patients initiating highly active antiretroviral therapy: a meta-analysis | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |